Cidara Therapeutics Announces Reverse Stock Split and Reports Q4 2023 Financial Results

Details

announced a reverse stock split of its common stock at a 1-for-20 ratio, effective April 23, 2024, to reduce the number of its outstanding shares to 20 million. This follows the approval by its stockholders on April 4, 2024. Additionally, the company reported its financial results for Q4 and the full year 2023, showing a total revenue of $63.9 million and a net loss of $22.9 million for the year. Cidara also highlighted its pipeline progress, including new data presented at various medical conferences and the approval of REZZAYO in the EU and UK for treating invasive candidiasis.

Items reported

Exhibits (2)

About Cidara Therapeutics Inc.

Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.